The Global Gastrointestinal Therapeutics Market size is expected to reach $45.9 billion by 2028, rising at a market growth of 3.8% CAGR during the forecast period.
Gastrointestinal disorders are associated with the digestive system and usually affect the colon, small & rectum, and large intestine. The conditions include constipation, irritable bowel syndrome, and peptic ulcer disease. The primary causes of GI disorders are stress, intake of medicines like iron pills and anti-depressants, or unhealthy eating habits.
Symptoms of gastrointestinal infections include pain, vomiting, bloating, nausea and vomiting. Various key areas in gastroenterology pharmacotherapy are rapidly evolving, including treating hepatitis C virus (HCV), gastroesophageal reflux disease (GERD), irritable bowel syndrome, and peptic ulcer disease.
HCV treatment has radically changed in the past few years, and now most patients are treatment candidates and have a higher likelihood of a permanent cure. Pharmacotherapy is now the first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the pillar of the therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects which should be kept in mind.
When dealing with new therapies, one should always consider whether they are safe, effective, and appropriate to the current treatments. That’s why a time-to-time review of the recent development in the field is required to provide a glimpse of what may lie ahead.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Gastrointestinal disorders are associated with the digestive system and usually affect the colon, small & rectum, and large intestine. The conditions include constipation, irritable bowel syndrome, and peptic ulcer disease. The primary causes of GI disorders are stress, intake of medicines like iron pills and anti-depressants, or unhealthy eating habits.
Symptoms of gastrointestinal infections include pain, vomiting, bloating, nausea and vomiting. Various key areas in gastroenterology pharmacotherapy are rapidly evolving, including treating hepatitis C virus (HCV), gastroesophageal reflux disease (GERD), irritable bowel syndrome, and peptic ulcer disease.
HCV treatment has radically changed in the past few years, and now most patients are treatment candidates and have a higher likelihood of a permanent cure. Pharmacotherapy is now the first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the pillar of the therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects which should be kept in mind.
When dealing with new therapies, one should always consider whether they are safe, effective, and appropriate to the current treatments. That’s why a time-to-time review of the recent development in the field is required to provide a glimpse of what may lie ahead.
COVID-19 Impact Analysis
The requirement for gastrointestinal therapeutics drugs is expected to remain constant due to the prevalence of GI symptoms through the diagnosis of COVID-19. This is because many of the patients" experience GI complications owing to this infection. Generally reported symptoms to include loss of appetite, nausea, diarrhea, abdominal pain, and others. Therefore, developing new drugs and products and launches, combined with the association of GI manifestations of SARS-CoV-2 with those exhibiting respiratory symptoms, is expected to surge the demand for gastrointestinal therapeutics procedures.Market Growth Factors
Rising Expenditure on Healthcare
One of the main factors boosting the market"s rise is the increasing size and number of investments made in the healthcare system by the government and private organizations of various nations. More developing countries would have greater access to high-quality healthcare due to the fast economic development and growing healthcare cost. Governments of different nations are working on expanding reimbursement options and improving inhabitants" access to good medical services.Robust Product Development
The rising incidence of gastrointestinal diseases, which ranges from severe to moderate, like ulcerative colitis, Crohn’s disease, and other gastrointestinal diseases, is surging the requirement for advanced therapeutics. As a result, biotechnology and pharmaceutical companies are concentrating more on R&D to discover and develop new products for treating gastrointestinal diseases, increasing their product pipeline. In addition, the increasing development of drugs for gastrointestinal disorders by vendors globally is expected to add to the growth.Market Restraining Factor
Gastrointestinal Cases Cannot Be Permanently Cured
Chronic gastritis is a common inflammatory disease. In numerous patients, the inflamed gastric mucosa showcases a gradual tendency to become atrophic (atrophic gastritis). Gastritis is generally lifelong, and spontaneous healing is rare with very few expectations, like patients with autoimmune chronic corpus gastritis. Gastritis is connected with the presence of the bacterium Helicobacter pylori. Inflammation and atrophy of the gastric mucosa result in the impairment of gastric secretory functions, for instance, pepsin, secretion of gastric acid, and gastrin. Thus, the absence of proper and permanent treatment for the gastrointestinal disease is expected to hinder the gastrointestinal therapeutics market growth.Type Outlook
Based on type, the gastrointestinal therapeutics market is segmented branded and generics. The branded segment garnered the highest revenue share in the gastrointestinal therapeutics market in 2021. This is due to the factors like the strong commercial performance of the branded gastrointestinal therapeutics, promising investigational pipeline candidates joined with the premium prices, and market exclusivity. Also, the rising regulatory approvals of branded drugs are anticipated to grow the segment’s growth in the projected period.
Drug Class Outlook
By drug class, the gastrointestinal therapeutics market is fragmented into aminosalicylates, digestive enzymes, proton pump inhibitors, laxatives, anti-emetics, H2 antagonists, anti-diarrheal, biologics/biosimilar and others. The antidiarrheal segment recorded a significant revenue share in the gastrointestinal therapeutics market in 2021. This is due to their usage in the treatment of chronic and acute diseases. They help to reduce the urgency and frequency of the stools passing while also assisting in easing pain, especially if the patient has cramping pain. Antidiarrheal can also be used without the description of a doctor.Route Of Administration Outlook
On the basis of route of administration, the gastrointestinal therapeutics market is divided into oral, injectable and others. The injectable segment acquired the highest revenue share in the gastrointestinal therapeutics market in 2021. The higher the adoption rate of the biological drugs, the higher prices, rapid onset of action, higher bioavailability, and less possibility of first-pass metabolism in the case of injectable medications are the factors responsible for market’s expansion.Application Outlook
By application, the gastrointestinal therapeutics market is classified into crohn’s disease, ulcerative colitis, GERD, IBS and others. The crohn’s disease segment garnered the maximum revenue share in the gastrointestinal therapeutics market in 2021. This is due to the increasing incidences of the Crohn’s diseases (CD) in the last 5 decades, the rising approval of the novel drugs for CD and the numerous diagnostic techniques for the Crohn’s disease like imaging modalities or serological markers which are helping in both monitoring and diagnosis, are expected to increase the market for crohn’s disease in the projected period.Distribution Channel Outlook
Based on distribution channel, the gastrointestinal therapeutics market is bifurcated into hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacies segment recorded a substantial revenue share in the gastrointestinal therapeutics market in 2021. This is due to the growing internet penetration, rising online pharmacies trends, and numerous discounts offered by online pharma players. Also, the adoption of telemedicine has increased during the pandemic, which is still growing even after COVID-19, is expected to further raise the market segment in the forecasted period.Regional Outlook
Region wise, the gastrointestinal therapeutics market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region acquired the highest revenue share in the gastrointestinal therapeutics market in 2021. The region’s growth is result of the presence of many market players in the area, joined with the various strategic initiatives they used. Moreover, there is an increase in disease prevalence and numerous government-funded schemes to promote research activities for gastrointestinal therapeutics, which are increasing the market in the region.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Strategies Deployed in Gastrointestinal Therapeutics Market
- Nov-2022: AbbVie received the European Commission Approval for SKYRIZI, a prescription medicine used to treat adults with moderate to severe Crohn"s disease and plaque psoriasis. The approval in European Union would add a breakthrough in AbbVie pursuit to broaden its inflammatory bowel disease portfolio.
- Oct-2022: Pfizer came into partnership with Erasca, a California-based clinical-stage precision oncology company to perform the trials of Palbociclib, an inhibitor of CDK4/6. This partnership for trial will allow companies to clinically test the drug along with ERAS-007 for the cure of NRAS-mutant colorectal cancer (CRC) and KRAS-mutant pancreatic ductal adenocarcinoma.
- Mar-2022: AbbVie received FDA approval for RINVOQ, a prescription medicine used to treat adults with moderate to severe ulcerative colitis. Through the approval of RINVOQ as a treatment option, AbbVie continues its advanced research which could help and influence the lives of people suffering from ulcerative colitis.
- Apr-2021: Bausch Health released ENVIVE, a Daily Probiotic Supplement. The product is particularly developed and tested clinically to deliver consumers a new multi-strain, preservative-free probiotic created to help alleviate periodic GI symptoms.
- May-2019: Takeda collaborated with Frazier Healthcare Partners, a provider of growth and venture capital to healthcare companies. This collaboration is aimed to advance Novel Therapeutics including Vonoprazan for the Treatment of Acid-Related Disorders in Europe and North America.
- Aug-2018: Takeda acquired TiGenix, a European cell therapy company. This acquisition would allow Takeda to deliver available options for the treatment of patients suffering from gastrointestinal disorders.
- Aug-2018: Takeda came into partnership with Ambys Medicines, a Biotechnology Research company. This partnership would help accelerate the capability of Takeda to provide regenerative medicine for people with liver ailments.
- Feb-2018: Janssen collaborated with Theravance BioPharma, a company involved in the development of respiratory medicines. This collaboration is for an oral, pan-jak inhibitor drug candidate for the cure of inflammatory bowel disease.
Scope of the Study
By Type
- Branded
- Generics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Route of Administration
- Injectable
- Oral & Others
By Application
- Crohn"s Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
By Drug Class
- Biologics/Biosimilar
- Anti-Diarrheal
- Anti-Emetics
- Digestive Enzymes
- Aminosalicylates
- Proton Pump Inhibitors
- Laxatives & H2 Antagonists
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Gastrointestinal Therapeutics Market, by Type
1.4.2 Global Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 Global Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 Global Gastrointestinal Therapeutics Market, by Application
1.4.5 Global Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 Global Gastrointestinal Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. Global Gastrointestinal Therapeutics Market by Type
4.1 Global Branded Market by Region
4.2 Global Generics Market by Region
Chapter 5. Global Gastrointestinal Therapeutics Market by Distribution Channel
5.1 Global Retail Pharmacies Market by Region
5.2 Global Hospital Pharmacies Market by Region
5.3 Global Online Pharmacies Market by Region
Chapter 6. Global Gastrointestinal Therapeutics Market by Route of Administration
6.1 Global Injectable Market by Region
6.2 Global Oral & Others Market by Region
Chapter 7. Global Gastrointestinal Therapeutics Market by Application
7.1 Global Crohn's Disease Market by Region
7.2 Global Ulcerative Colitis Market by Region
7.3 Global GERD Market by Region
7.4 Global IBS Market by Region
7.5 Global Others Market by Region
Chapter 8. Global Gastrointestinal Therapeutics Market by Drug Class
8.1 Global Biologics/Biosimilar Market by Region
8.2 Global Anti-Diarrheal Market by Region
8.3 Global Anti-Emetics Market by Region
8.4 Global Digestive Enzymes Market by Region
8.5 Global Aminosalicylates Market by Region
8.6 Global Proton Pump Inhibitors Market by Region
8.7 Global Laxatives & H2 Antagonists Market by Region
8.8 Global Others Market by Region
Chapter 9. Global Gastrointestinal Therapeutics Market by Region
9.1 North America Gastrointestinal Therapeutics Market
9.1.1 North America Gastrointestinal Therapeutics Market by Type
9.1.1.1 North America Branded Market by Country
9.1.1.2 North America Generics Market by Country
9.1.2 North America Gastrointestinal Therapeutics Market by Distribution Channel
9.1.2.1 North America Retail Pharmacies Market by Country
9.1.2.2 North America Hospital Pharmacies Market by Country
9.1.2.3 North America Online Pharmacies Market by Country
9.1.3 North America Gastrointestinal Therapeutics Market by Route of Administration
9.1.3.1 North America Injectable Market by Country
9.1.3.2 North America Oral & Others Market by Country
9.1.4 North America Gastrointestinal Therapeutics Market by Application
9.1.4.1 North America Crohn's Disease Market by Country
9.1.4.2 North America Ulcerative Colitis Market by Country
9.1.4.3 North America GERD Market by Country
9.1.4.4 North America IBS Market by Country
9.1.4.5 North America Others Market by Country
9.1.5 North America Gastrointestinal Therapeutics Market by Drug Class
9.1.5.1 North America Biologics/Biosimilar Market by Country
9.1.5.2 North America Anti-Diarrheal Market by Country
9.1.5.3 North America Anti-Emetics Market by Country
9.1.5.4 North America Digestive Enzymes Market by Country
9.1.5.5 North America Aminosalicylates Market by Country
9.1.5.6 North America Proton Pump Inhibitors Market by Country
9.1.5.7 North America Laxatives & H2 Antagonists Market by Country
9.1.5.8 North America Others Market by Country
9.1.6 North America Gastrointestinal Therapeutics Market by Country
9.1.6.1 US Gastrointestinal Therapeutics Market
9.1.6.1.1 US Gastrointestinal Therapeutics Market by Type
9.1.6.1.2 US Gastrointestinal Therapeutics Market by Distribution Channel
9.1.6.1.3 US Gastrointestinal Therapeutics Market by Route of Administration
9.1.6.1.4 US Gastrointestinal Therapeutics Market by Application
9.1.6.1.5 US Gastrointestinal Therapeutics Market by Drug Class
9.1.6.2 Canada Gastrointestinal Therapeutics Market
9.1.6.2.1 Canada Gastrointestinal Therapeutics Market by Type
9.1.6.2.2 Canada Gastrointestinal Therapeutics Market by Distribution Channel
9.1.6.2.3 Canada Gastrointestinal Therapeutics Market by Route of Administration
9.1.6.2.4 Canada Gastrointestinal Therapeutics Market by Application
9.1.6.2.5 Canada Gastrointestinal Therapeutics Market by Drug Class
9.1.6.3 Mexico Gastrointestinal Therapeutics Market
9.1.6.3.1 Mexico Gastrointestinal Therapeutics Market by Type
9.1.6.3.2 Mexico Gastrointestinal Therapeutics Market by Distribution Channel
9.1.6.3.3 Mexico Gastrointestinal Therapeutics Market by Route of Administration
9.1.6.3.4 Mexico Gastrointestinal Therapeutics Market by Application
9.1.6.3.5 Mexico Gastrointestinal Therapeutics Market by Drug Class
9.1.6.4 Rest of North America Gastrointestinal Therapeutics Market
9.1.6.4.1 Rest of North America Gastrointestinal Therapeutics Market by Type
9.1.6.4.2 Rest of North America Gastrointestinal Therapeutics Market by Distribution Channel
9.1.6.4.3 Rest of North America Gastrointestinal Therapeutics Market by Route of Administration
9.1.6.4.4 Rest of North America Gastrointestinal Therapeutics Market by Application
9.1.6.4.5 Rest of North America Gastrointestinal Therapeutics Market by Drug Class
9.2 Europe Gastrointestinal Therapeutics Market
9.2.1 Europe Gastrointestinal Therapeutics Market by Type
9.2.1.1 Europe Branded Market by Country
9.2.1.2 Europe Generics Market by Country
9.2.2 Europe Gastrointestinal Therapeutics Market by Distribution Channel
9.2.2.1 Europe Retail Pharmacies Market by Country
9.2.2.2 Europe Hospital Pharmacies Market by Country
9.2.2.3 Europe Online Pharmacies Market by Country
9.2.3 Europe Gastrointestinal Therapeutics Market by Route of Administration
9.2.3.1 Europe Injectable Market by Country
9.2.3.2 Europe Oral & Others Market by Country
9.2.4 Europe Gastrointestinal Therapeutics Market by Application
9.2.4.1 Europe Crohn's Disease Market by Country
9.2.4.2 Europe Ulcerative Colitis Market by Country
9.2.4.3 Europe GERD Market by Country
9.2.4.4 Europe IBS Market by Country
9.2.4.5 Europe Others Market by Country
9.2.5 Europe Gastrointestinal Therapeutics Market by Drug Class
9.2.5.1 Europe Biologics/Biosimilar Market by Country
9.2.5.2 Europe Anti-Diarrheal Market by Country
9.2.5.3 Europe Anti-Emetics Market by Country
9.2.5.4 Europe Digestive Enzymes Market by Country
9.2.5.5 Europe Aminosalicylates Market by Country
9.2.5.6 Europe Proton Pump Inhibitors Market by Country
9.2.5.7 Europe Laxatives & H2 Antagonists Market by Country
9.2.5.8 Europe Others Market by Country
9.2.6 Europe Gastrointestinal Therapeutics Market by Country
9.2.6.1 Germany Gastrointestinal Therapeutics Market
9.2.6.1.1 Germany Gastrointestinal Therapeutics Market by Type
9.2.6.1.2 Germany Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.1.3 Germany Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.1.4 Germany Gastrointestinal Therapeutics Market by Application
9.2.6.1.5 Germany Gastrointestinal Therapeutics Market by Drug Class
9.2.6.2 UK Gastrointestinal Therapeutics Market
9.2.6.2.1 UK Gastrointestinal Therapeutics Market by Type
9.2.6.2.2 UK Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.2.3 UK Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.2.4 UK Gastrointestinal Therapeutics Market by Application
9.2.6.2.5 UK Gastrointestinal Therapeutics Market by Drug Class
9.2.6.3 France Gastrointestinal Therapeutics Market
9.2.6.3.1 France Gastrointestinal Therapeutics Market by Type
9.2.6.3.2 France Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.3.3 France Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.3.4 France Gastrointestinal Therapeutics Market by Application
9.2.6.3.5 France Gastrointestinal Therapeutics Market by Drug Class
9.2.6.4 Russia Gastrointestinal Therapeutics Market
9.2.6.4.1 Russia Gastrointestinal Therapeutics Market by Type
9.2.6.4.2 Russia Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.4.3 Russia Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.4.4 Russia Gastrointestinal Therapeutics Market by Application
9.2.6.4.5 Russia Gastrointestinal Therapeutics Market by Drug Class
9.2.6.5 Spain Gastrointestinal Therapeutics Market
9.2.6.5.1 Spain Gastrointestinal Therapeutics Market by Type
9.2.6.5.2 Spain Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.5.3 Spain Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.5.4 Spain Gastrointestinal Therapeutics Market by Application
9.2.6.5.5 Spain Gastrointestinal Therapeutics Market by Drug Class
9.2.6.6 Italy Gastrointestinal Therapeutics Market
9.2.6.6.1 Italy Gastrointestinal Therapeutics Market by Type
9.2.6.6.2 Italy Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.6.3 Italy Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.6.4 Italy Gastrointestinal Therapeutics Market by Application
9.2.6.6.5 Italy Gastrointestinal Therapeutics Market by Drug Class
9.2.6.7 Rest of Europe Gastrointestinal Therapeutics Market
9.2.6.7.1 Rest of Europe Gastrointestinal Therapeutics Market by Type
9.2.6.7.2 Rest of Europe Gastrointestinal Therapeutics Market by Distribution Channel
9.2.6.7.3 Rest of Europe Gastrointestinal Therapeutics Market by Route of Administration
9.2.6.7.4 Rest of Europe Gastrointestinal Therapeutics Market by Application
9.2.6.7.5 Rest of Europe Gastrointestinal Therapeutics Market by Drug Class
9.3 Asia Pacific Gastrointestinal Therapeutics Market
9.3.1 Asia Pacific Gastrointestinal Therapeutics Market by Type
9.3.1.1 Asia Pacific Branded Market by Country
9.3.1.2 Asia Pacific Generics Market by Country
9.3.2 Asia Pacific Gastrointestinal Therapeutics Market by Distribution Channel
9.3.2.1 Asia Pacific Retail Pharmacies Market by Country
9.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
9.3.2.3 Asia Pacific Online Pharmacies Market by Country
9.3.3 Asia Pacific Gastrointestinal Therapeutics Market by Route of Administration
9.3.3.1 Asia Pacific Injectable Market by Country
9.3.3.2 Asia Pacific Oral & Others Market by Country
9.3.4 Asia Pacific Gastrointestinal Therapeutics Market by Application
9.3.4.1 Asia Pacific Crohn's Disease Market by Country
9.3.4.2 Asia Pacific Ulcerative Colitis Market by Country
9.3.4.3 Asia Pacific GERD Market by Country
9.3.4.4 Asia Pacific IBS Market by Country
9.3.4.5 Asia Pacific Others Market by Country
9.3.5 Asia Pacific Gastrointestinal Therapeutics Market by Drug Class
9.3.5.1 Asia Pacific Biologics/Biosimilar Market by Country
9.3.5.2 Asia Pacific Anti-Diarrheal Market by Country
9.3.5.3 Asia Pacific Anti-Emetics Market by Country
9.3.5.4 Asia Pacific Digestive Enzymes Market by Country
9.3.5.5 Asia Pacific Aminosalicylates Market by Country
9.3.5.6 Asia Pacific Proton Pump Inhibitors Market by Country
9.3.5.7 Asia Pacific Laxatives & H2 Antagonists Market by Country
9.3.5.8 Asia Pacific Others Market by Country
9.3.6 Asia Pacific Gastrointestinal Therapeutics Market by Country
9.3.6.1 China Gastrointestinal Therapeutics Market
9.3.6.1.1 China Gastrointestinal Therapeutics Market by Type
9.3.6.1.2 China Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.1.3 China Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.1.4 China Gastrointestinal Therapeutics Market by Application
9.3.6.1.5 China Gastrointestinal Therapeutics Market by Drug Class
9.3.6.2 Japan Gastrointestinal Therapeutics Market
9.3.6.2.1 Japan Gastrointestinal Therapeutics Market by Type
9.3.6.2.2 Japan Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.2.3 Japan Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.2.4 Japan Gastrointestinal Therapeutics Market by Application
9.3.6.2.5 Japan Gastrointestinal Therapeutics Market by Drug Class
9.3.6.3 India Gastrointestinal Therapeutics Market
9.3.6.3.1 India Gastrointestinal Therapeutics Market by Type
9.3.6.3.2 India Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.3.3 India Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.3.4 India Gastrointestinal Therapeutics Market by Application
9.3.6.3.5 India Gastrointestinal Therapeutics Market by Drug Class
9.3.6.4 South Korea Gastrointestinal Therapeutics Market
9.3.6.4.1 South Korea Gastrointestinal Therapeutics Market by Type
9.3.6.4.2 South Korea Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.4.3 South Korea Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.4.4 South Korea Gastrointestinal Therapeutics Market by Application
9.3.6.4.5 South Korea Gastrointestinal Therapeutics Market by Drug Class
9.3.6.5 Singapore Gastrointestinal Therapeutics Market
9.3.6.5.1 Singapore Gastrointestinal Therapeutics Market by Type
9.3.6.5.2 Singapore Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.5.3 Singapore Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.5.4 Singapore Gastrointestinal Therapeutics Market by Application
9.3.6.5.5 Singapore Gastrointestinal Therapeutics Market by Drug Class
9.3.6.6 Malaysia Gastrointestinal Therapeutics Market
9.3.6.6.1 Malaysia Gastrointestinal Therapeutics Market by Type
9.3.6.6.2 Malaysia Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.6.3 Malaysia Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.6.4 Malaysia Gastrointestinal Therapeutics Market by Application
9.3.6.6.5 Malaysia Gastrointestinal Therapeutics Market by Drug Class
9.3.6.7 Rest of Asia Pacific Gastrointestinal Therapeutics Market
9.3.6.7.1 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Type
9.3.6.7.2 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Distribution Channel
9.3.6.7.3 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Route of Administration
9.3.6.7.4 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Application
9.3.6.7.5 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Drug Class
9.4 LAMEA Gastrointestinal Therapeutics Market
9.4.1 LAMEA Gastrointestinal Therapeutics Market by Type
9.4.1.1 LAMEA Branded Market by Country
9.4.1.2 LAMEA Generics Market by Country
9.4.2 LAMEA Gastrointestinal Therapeutics Market by Distribution Channel
9.4.2.1 LAMEA Retail Pharmacies Market by Country
9.4.2.2 LAMEA Hospital Pharmacies Market by Country
9.4.2.3 LAMEA Online Pharmacies Market by Country
9.4.3 LAMEA Gastrointestinal Therapeutics Market by Route of Administration
9.4.3.1 LAMEA Injectable Market by Country
9.4.3.2 LAMEA Oral & Others Market by Country
9.4.4 LAMEA Gastrointestinal Therapeutics Market by Application
9.4.4.1 LAMEA Crohn's Disease Market by Country
9.4.4.2 LAMEA Ulcerative Colitis Market by Country
9.4.4.3 LAMEA GERD Market by Country
9.4.4.4 LAMEA IBS Market by Country
9.4.4.5 LAMEA Others Market by Country
9.4.5 LAMEA Gastrointestinal Therapeutics Market by Drug Class
9.4.5.1 LAMEA Biologics/Biosimilar Market by Country
9.4.5.2 LAMEA Anti-Diarrheal Market by Country
9.4.5.3 LAMEA Anti-Emetics Market by Country
9.4.5.4 LAMEA Digestive Enzymes Market by Country
9.4.5.5 LAMEA Aminosalicylates Market by Country
9.4.5.6 LAMEA Proton Pump Inhibitors Market by Country
9.4.5.7 LAMEA Laxatives & H2 Antagonists Market by Country
9.4.5.8 LAMEA Others Market by Country
9.4.6 LAMEA Gastrointestinal Therapeutics Market by Country
9.4.6.1 Brazil Gastrointestinal Therapeutics Market
9.4.6.1.1 Brazil Gastrointestinal Therapeutics Market by Type
9.4.6.1.2 Brazil Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.1.3 Brazil Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.1.4 Brazil Gastrointestinal Therapeutics Market by Application
9.4.6.1.5 Brazil Gastrointestinal Therapeutics Market by Drug Class
9.4.6.2 Argentina Gastrointestinal Therapeutics Market
9.4.6.2.1 Argentina Gastrointestinal Therapeutics Market by Type
9.4.6.2.2 Argentina Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.2.3 Argentina Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.2.4 Argentina Gastrointestinal Therapeutics Market by Application
9.4.6.2.5 Argentina Gastrointestinal Therapeutics Market by Drug Class
9.4.6.3 UAE Gastrointestinal Therapeutics Market
9.4.6.3.1 UAE Gastrointestinal Therapeutics Market by Type
9.4.6.3.2 UAE Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.3.3 UAE Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.3.4 UAE Gastrointestinal Therapeutics Market by Application
9.4.6.3.5 UAE Gastrointestinal Therapeutics Market by Drug Class
9.4.6.4 Saudi Arabia Gastrointestinal Therapeutics Market
9.4.6.4.1 Saudi Arabia Gastrointestinal Therapeutics Market by Type
9.4.6.4.2 Saudi Arabia Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.4.3 Saudi Arabia Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.4.4 Saudi Arabia Gastrointestinal Therapeutics Market by Application
9.4.6.4.5 Saudi Arabia Gastrointestinal Therapeutics Market by Drug Class
9.4.6.5 South Africa Gastrointestinal Therapeutics Market
9.4.6.5.1 South Africa Gastrointestinal Therapeutics Market by Type
9.4.6.5.2 South Africa Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.5.3 South Africa Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.5.4 South Africa Gastrointestinal Therapeutics Market by Application
9.4.6.5.5 South Africa Gastrointestinal Therapeutics Market by Drug Class
9.4.6.6 Nigeria Gastrointestinal Therapeutics Market
9.4.6.6.1 Nigeria Gastrointestinal Therapeutics Market by Type
9.4.6.6.2 Nigeria Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.6.3 Nigeria Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.6.4 Nigeria Gastrointestinal Therapeutics Market by Application
9.4.6.6.5 Nigeria Gastrointestinal Therapeutics Market by Drug Class
9.4.6.7 Rest of LAMEA Gastrointestinal Therapeutics Market
9.4.6.7.1 Rest of LAMEA Gastrointestinal Therapeutics Market by Type
9.4.6.7.2 Rest of LAMEA Gastrointestinal Therapeutics Market by Distribution Channel
9.4.6.7.3 Rest of LAMEA Gastrointestinal Therapeutics Market by Route of Administration
9.4.6.7.4 Rest of LAMEA Gastrointestinal Therapeutics Market by Application
9.4.6.7.5 Rest of LAMEA Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Methodology
LOADING...
